Cytos Biotechnology AG Aiming for Lucrative Asthma Drug Deal Worth $541 Million According to CEO  
6/24/2010 11:26:37 AM

Reuters -- Swiss biotech company Cytos (CYTN.S) is aiming to clinch a partnering deal worth over 600 million Swiss francs ($541 million) for its asthma vaccine after strong mid-trial data, the group's head was quoted as saying.